MedPath

Clinical Trial News

ASTRO 2024: Radiotherapy Innovations and the Space-Time Continuum in Metastatic Castration-Sensitive Prostate Cancer

• Dr. Phuoc Tran highlighted that 'space' (metastatic volume) and 'time' (synchronous vs. metachronous presentation) are clinical manifestations of metastatic biology in mCSPC. • STAMPEDE Arm H trial data suggests a significant overall survival benefit from prostate radiotherapy in patients with low-volume metastatic disease (≤5 lesions). • Phase II trials like STOMP, ORIOLE, and SABR-COMET support metastasis-directed therapy (MDT) with SBRT for oligorecurrent mCSPC, improving ADT-free and progression-free survival.

TERPS Trial for de Novo Oligometastic Prostate Cancer

NCT05223803RecruitingPhase 2
University of Maryland, Baltimore
Posted 10/18/2022

The Alarm's Mike Peters Achieves Remission from Richter's Syndrome Through NHS Drug Trial

  • Mike Peters, frontman of The Alarm, achieved remission from aggressive Richter's syndrome after participating in an NHS drug trial at The Christie in Manchester.
  • The trial combined acalabrutinib, a targeted therapy already approved for CLL, with standard chemotherapy, showing promising results in treating Richter's syndrome.
  • Doctors plan to proceed with a stem cell transplant to prevent the recurrence of leukemia, offering Peters a chance for a complete cure.
  • Professor Adrian Bloor highlights the potential of the acalabrutinib combination to effectively treat Richter's syndrome and prevent its return.

Device-Assisted Dopamine Therapy and TAK-071 Show Promise in Parkinson's Disease

  • A device-assisted therapy delivering dopamine directly to the brain shows potential in treating Parkinson's disease by improving symptom control without dyskinesia.
  • TAK-071, an acetylcholine M1 receptor positive allosteric modulator, improved cognition in Parkinson's patients with cognitive impairment in a Phase 2 trial.
  • Subcutaneous carbidopa/levodopa demonstrates improved motor function, daily activities, sleep, and quality of life compared to oral formulations for Parkinson's.
  • Adaptive deep brain stimulation (DBS) is preferred by patients and may become the standard of care, offering personalized electrical stimulation based on brain activity.

A Study of TAK-071 in People With Parkinson Disease

NCT04334317CompletedPhase 2
Takeda
Posted 10/21/2020

Blockchain Technology Emerges as Key Weapon Against $200B Counterfeit Drug Market

  • WHO reports approximately 1 in 10 medical products in low and middle-income countries are substandard or falsified, highlighting the critical need for supply chain security solutions.
  • Blockchain technology offers a decentralized, transparent approach to combat counterfeit drugs, with projects like MediLedger demonstrating practical applications in pharmaceutical supply chain tracking.
  • Despite the $200 billion counterfeit drug market threat, industry adoption faces challenges including standardization issues, data sharing concerns, and regulatory hurdles.

Cognitive Function May Fully Recover After Cranial Radiation for Brain Metastases

  • A pooled analysis of Phase III clinical trials reveals that cognitive side effects following cranial radiation therapy for brain metastases may be fully reversible.
  • Conformal radiation techniques, such as stereotactic radiosurgery (SRS) and hippocampal avoidance WBRT, are more likely to result in cognitive recovery compared to whole-brain radiation therapy (WBRT).
  • Six months after cognitive decline, 38% of patients experienced full cognitive recovery, increasing to 42% at one year, with even more showing some cognitive improvement.
  • The findings suggest that cognitive dysfunction should not be viewed as a permanent endpoint, offering hope for improved long-term quality of life for patients with brain metastases.

Short-Term ADT Plus High-Dose Radiotherapy Improves Outcomes in Localized Prostate Cancer

  • A phase 3 trial (GETUG 14) reveals that combining short-term androgen deprivation therapy (ADT) with high-dose radiotherapy improves disease-free survival in localized prostate cancer patients.
  • The addition of ADT significantly reduces the risk of biochemical failure but does not significantly impact metastasis failure or overall survival.
  • Patients with intermediate-risk prostate cancer showed a notable improvement in 5-year disease-free survival with the combined therapy compared to radiotherapy alone.
  • The combination therapy did not increase gastrointestinal or genitourinary toxicities, but a higher rate of early erectile dysfunction was observed with ADT.

Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00104741CompletedPhase 3
UNICANCER
Posted 9/10/2003

APAC Clinical Services Market Set to Reach $140 Billion by 2031 as Region Emerges as Trial Powerhouse

  • The Asia-Pacific region has become a clinical trial powerhouse, contributing nearly 50% of new global trial activity and offering diverse patient demographics for expedited enrollment.
  • Clinical services organizations are helping pharmaceutical companies navigate complex regulatory requirements and cold-chain challenges, particularly for biologics and cell therapies.
  • The APAC clinical services/CDMO market is projected to reach $140 billion by 2031, driven by increasing demand for generic medicines and complex trial requirements.

Proton Beam Therapy and IMRT Show Equivalent Outcomes in Prostate Cancer Treatment

  • A phase III clinical trial (PARTIQoL) comparing proton beam therapy (PBT) and intensity modulated radiation therapy (IMRT) for localized prostate cancer found similar rates of tumor control.
  • Patient-reported quality of life, including bowel, urinary, and sexual function, showed no significant differences between the two treatment modalities over a 5-year follow-up.
  • Progression-free survival rates were comparable, with 93.7% for IMRT and 93.4% for PBT, indicating similar efficacy in preventing tumor progression.
  • The study suggests either PBT or IMRT can be effectively used for localized prostate cancer, with treatment decisions potentially based on other factors like cost and availability.

Editas Medicine's Reni-Cel Shows Promise in Sickle Cell Disease Treatment

  • Editas Medicine's reni-cel (EDIT-301) demonstrates a 100% vaso-occlusive crises-free rate in SCD patients during follow-up, with sustained hemoglobin levels.
  • The RUBY trial's adult cohort enrollment is complete, and adolescent enrollment is underway, with data updates expected in mid and late 2024.
  • Editas aims for regulatory filing in the second half of 2025, positioning itself in the competitive gene editing market alongside CRISPR Therapeutics and Vertex Pharmaceuticals.
  • The company's strong patent estate and focus on up-regulation techniques for in vivo treatments could provide a competitive edge.

177Lu-Dotatate Shows Promise in Refractory Meningioma Treatment

  • A Phase II trial of 177Lu-Dotatate in recurrent meningioma met its primary endpoint, demonstrating improved progression-free survival.
  • The median progression-free survival was 11.5 months, with a 2-year PFS rate of 26.7%, marking a significant improvement over historical benchmarks.
  • The radiopharmaceutical therapy was well-tolerated, suggesting it is a safe and rational therapeutic choice for refractory meningioma.
  • These findings establish a new benchmark for treating refractory meningioma, potentially influencing future treatment options.

Trending News

1

Apellis Secures $300 Million in Non-Dilutive Financing Through Sobi Royalty Agreement for Rare Kidney Disease Therapy

3 days ago
2

Organon Discontinues Endometriosis Drug OG-6219 After Phase II Trial Failure

a day ago
3

Lixte Biotechnology Secures $5 Million Private Placement to Advance Cancer Therapy Development

2 days ago
4

Pfizer Terminates Phase II CD47 Trial in Blood Cancer Due to Recruitment Challenges

2 days ago
5

FDA Clears IND for IKS014 HER2-Targeted ADC, Enabling US Clinical Trial Expansion

3 days ago
6

Argenx Partners with Unnatural Products in $1.5 Billion Macrocyclic Peptide Deal

2 days ago
7

Ambroxol Shows Promise in Slowing Parkinson's Disease Dementia in Phase II Clinical Trial

3 days ago
8

HanchorBio Secures $202M Licensing Deal with Henlius for Novel CD47-Targeting Cancer Immunotherapy

2 days ago
9

Genenta Reports 3-Year Survival in Glioblastoma Patients with Temferon Cell Therapy

3 days ago
10

PharmNovo Advances Non-Addictive Neuropathic Pain Drug PN6047 with Phase 2 Trial Application

2 days ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy